Friday, January 02, 2026 | 02:02 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

DCGI allows Serum to enrol 7-11 year olds in Covid vaccine trial

So far, only drugmaker Zydus Cadila's DNA Covid vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above

Along with shorter-lasting antibodies, Covid vaccines also trigger what’s essentially a long-term memory in the immune system. (Photo: Bloomberg)
premium

Representative image of Covid vaccine shots (Agencies/File)

Reuters Bengaluru
India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect children from the coronavirus.
 
It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.
 
"After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol," a subject expert panel of the Central Drugs Standard Control Organization said.
 
Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of AstraZeneca's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.
 
So far, only drugmaker Zydus Cadila's DNA COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)